DAPHNe: De-escalation to adjuvant antibodies post-pCR to Neoadjuvant THP (paclitaxel/trastuzumab/pertuzumab) - a pilot study in HER-2 positive breast cancer (DF/HCC 18-394)
This research study is studying whether participants and their doctors are willing to determine post-surgery treatment on the basis of response to pre-surgery treatment, and studying blood and tissue collected from participants treated with a combination of drugs as a treatment for breast cancer.
The names study drugs involved in this study are:
- Paclitaxel (also called Taxol)
- Trastuzumab (also called Herceptin)
- Pertuzumab (also called Perjeta)